Skip to main content
SpringerLink
Log in
Book cover

Helicobacter pylori pp 427–436Cite as

Triple Therapy

  • Chapter
  • First Online:

  • 1939 Accesses

Abstract

Triple therapy has long been used as the first-line therapy for Helicobacter pylori (H. pylori) infection, but its efficacy has been continuously decreasing over the past 10 years. The main cause of decrease in the H. pylori eradication rate of conventional triple therapy is increasing resistance of H. pylori to clarithromycin. The H. pylori-associated factors affecting the eradication rate of conventional triple therapy are antibiotic resistance, colonization density of H. pylori in the gastric mucosal membrane, and virulence factors of cagA and vacA. Host factors are medication adherence, excess gastric acid secretion, cytochrome P450 gene polymorphism (CYP2C19), treatment duration, drug side effects, underlying gastroduodenal disease, gastritis pattern, smoking, diabetes, obesity, etc. Due to decrease in the H. pylori eradication rate of the triple therapy, the current standard first-line treatment for H. pylori infection, it has become necessary to develop a new first-line treatment capable of increasing the H. pylori eradication rate.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Malfertheiner P, Megraud F, O’Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of Helicobacter pylori infection – the Maastricht consensus report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol. 1997;9:1–2.

    Article  CAS  PubMed  Google Scholar 

  2. Korean H. pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J Gastroenterol. 1998;32:275–89.

    Google Scholar 

  3. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009;54:269–78.

    Article  PubMed  Google Scholar 

  4. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371–86.

    Article  PubMed  Google Scholar 

  5. Lee JY, Kim N. Future trends of Helicobacter pylori eradication therapy in Korea. Korean J Gastroenterol. 2014;63:158–70.

    Article  PubMed  Google Scholar 

  6. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–53.

    Article  CAS  PubMed  Google Scholar 

  7. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection – the Maastricht IV/florence consensus report. Gut. 2012;61:646–64.

    Article  CAS  PubMed  Google Scholar 

  8. Heo J, Jeon SW. Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2014;63:141–5.

    Article  PubMed  Google Scholar 

  9. Jung YS, Lee SH, Park CS, Oh MJ, Kim KO, Jang BI, et al. Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years. Korean J Gastroenterol. 2014;63:82–9.

    Article  PubMed  Google Scholar 

  10. Yoon KH, Park SW, Lee SW, Kim BJ, Kim JG. Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. J Korean Med Sci. 2014;29:1240–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT, et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol. 2012;18:6628–34.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gong EJ, Yun SC, Jung HY, Lim H, Choi KS, Ahn JY, et al. Meta-analysis of first-line triple therapy for Helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci. 2014;29:704–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kim JY, Kim NY, Kim SJ, Baik GH, Kim GH, Kim JM, et al. Regional difference of antibiotic resistance of Helicobacter pylori strains in Korea. Korean J Gastroenterol. 2011;57:221–9.

    Article  PubMed  Google Scholar 

  14. Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci. 2014;59:1235–43.

    Article  CAS  PubMed  Google Scholar 

  15. Zullo A, De Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks! J Clin Gastroenterol. 2012;46:259–61.

    Article  PubMed  Google Scholar 

  16. Nishizawa T, Suzuki H, Suzuki M, Takahashi M, Hibi T. Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. J Clin Biochem Nutr. 2012;51:114–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol. 2012;27:504–9.

    Article  CAS  PubMed  Google Scholar 

  18. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106:1970–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther. 1998;12:383–8.

    Article  CAS  PubMed  Google Scholar 

  20. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’. Aliment Pharmacol Ther. 2001;15:1023–9.

    Article  CAS  PubMed  Google Scholar 

  21. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409–14.

    PubMed  Google Scholar 

  22. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007;45:4006–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.

    Article  CAS  PubMed  Google Scholar 

  24. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998–2002. Dig Liver Dis. 2003;35:541–5.

    Article  CAS  PubMed  Google Scholar 

  25. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58:930–5.

    Article  CAS  PubMed  Google Scholar 

  26. Asrat D, Kassa E, Mengistu Y, Nilsson I, Wadstrom T. Antimicrobial susceptibility pattern of Helicobacter pylori strains isolated from adult dyspeptic patients in Tikur Anbassa University Hospital, Addis Ababa, Ethiopia. Ethiop Med J. 2004;42:79–85.

    PubMed  Google Scholar 

  27. Nahar S, Mukhopadhyay AK, Khan R, Ahmad MM, Datta S, Chattopadhyay S, et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol. 2004;42:4856–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010;8:59–70.

    Article  CAS  PubMed  Google Scholar 

  29. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother. 2004;48:4843–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, et al. Prevalence of primary and secondary antimicrobial resistance of pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206–14.

    Article  CAS  PubMed  Google Scholar 

  31. Perri F, Clemente R, Festa V, Quitadamo M, Conoscitore P, Niro G, et al. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol. 1998;30:146–50.

    CAS  PubMed  Google Scholar 

  32. Lai YC, Yang JC, Huang SH. Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. World J Gastroenterol. 2004;10:991–4.

    PubMed  PubMed Central  Google Scholar 

  33. Molnar B, Szoke D, Ruzsovics A, Tulassay Z. Significantly elevated Helicobacter pylori density and different genotype distribution in erosions as compared with normal gastric biopsy specimen detected by quantitative real-time PCR. Eur J Gastroenterol Hepatol. 2008;20:305–13.

    Article  PubMed  Google Scholar 

  34. Aggarwal N, Snyder P, Owens SR. Unusual Helicobacter pylori in gastric resection specimens: an old friend with a new look. Int J Surg Pathol. 2011;19:297–302.

    Article  PubMed  Google Scholar 

  35. Andersen LP, Rasmussen L. Helicobacter pylori-coccoid forms and biofilm formation. FEMS Immunol Med Microbiol. 2009;56:112–5.

    Article  CAS  PubMed  Google Scholar 

  36. Suzuki T, Matsuo K, Sawaki A, Ito H, Hirose K, Wakai K, et al. Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;24:273–80.

    Article  CAS  PubMed  Google Scholar 

  37. van Doorn LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WG, de Boer WA. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut. 2000;46:321–26.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Shiota S, Nguyen LT, Murakami K, Kuroda A, Mizukami K, Okimoto T, et al. Association of Helicobacter pylori dupA with the failure of primary eradication. J Clin Gastroenterol. 2012;46:297–301.

    Article  PubMed  PubMed Central  Google Scholar 

  39. De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther. 2012;3:68–73.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008;148:923–31.

    Article  PubMed  Google Scholar 

  42. Vakil N, Vaira D. Treatment for H. pylori infection: new challenges with antimicrobial resistance. J Clin Gastroenterol. 2013;47:383–8.

    Article  CAS  PubMed  Google Scholar 

  43. Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol. 2012;5:49–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy: clinical implications. Am J Pharmacogenomics. 2003;3:303–15.

    Article  CAS  PubMed  Google Scholar 

  45. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy. 2003;23:460–71.

    Article  CAS  PubMed  Google Scholar 

  46. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101:1467–75.

    Article  CAS  PubMed  Google Scholar 

  47. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36:414–25.

    Article  CAS  PubMed  Google Scholar 

  48. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008;13:532–41.

    Article  PubMed  Google Scholar 

  49. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS ONE. 2013;8:e62162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH. The influence of CYP2C19 polymorphism on eradication of Helicobacter pylori: a prospective randomized study of lansoprazole and rabeprazole. Gut Liver. 2010;4:201–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kang JM, Kim N, Lee DH, Park YS, Kim JS, Chang IJ, et al. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol. 2008;23:1287–91.

    Article  CAS  PubMed  Google Scholar 

  52. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–600.

    Article  PubMed  Google Scholar 

  53. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603–9.

    Article  CAS  PubMed  Google Scholar 

  54. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147:553–62.

    Article  PubMed  Google Scholar 

  55. Kang JH, Lim YJ. Trend for treatment of Helicobacter pylori in overseas country. Korean J Helicobacter Up Gastrointest Res. 2012;12:224–31.

    Article  Google Scholar 

  56. Kim BG, Lee DH, Ye BD, Lee KH, Kim BW, Kim SG, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter. 2007;12:31–5.

    Article  CAS  PubMed  Google Scholar 

  57. Kang BK, Kim BW. Helicobacter pylori virulence factors and host factors. Korean J Helicobacter Up Gastrointest Res. 2011;11:7–12.

    Article  Google Scholar 

  58. Heo J, Jeon SW. Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. World J Gastroenterol. 2014;20:5654–9.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther. 2009;34:41–53.

    Article  CAS  PubMed  Google Scholar 

  60. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol. 2001;13:1303–7.

    Article  CAS  PubMed  Google Scholar 

  61. Zullo A, Rinaldi V, Hassan C, Taggi F, Giustini M, Winn S, et al. Clinical and histologic predictors of Helicobacter pylori infection recurrence. J Clin Gastroenterol. 2000;31:38–41.

    Article  CAS  PubMed  Google Scholar 

  62. Zullo A, Severi C, Vannella L, Hassan C, Sbrozzi-Vanni A, Annibale B. Role of gastritis pattern on Helicobacter pylori eradication. Intern Emerg Med. 2012;7:517–22.

    Article  PubMed  Google Scholar 

  63. Severi C, Abdullahi M, Tari R, Vannella L, Marcheggiano A, Capoccia D, et al. High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis. Dig Liver Dis. 2009;41:555–8.

    Article  CAS  PubMed  Google Scholar 

  64. Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119:217–24.

    Article  PubMed  Google Scholar 

  65. Namiot DB, Leszczynska K, Namiot Z, Kurylonek AJ, Kemona A. Smoking and drinking habits are important predictors of Helicobacter pylori eradication. Adv Med Sci. 2008;53:310–5.

    Article  CAS  PubMed  Google Scholar 

  66. De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Berloco P, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther. 2004;19:407–14.

    Article  PubMed  Google Scholar 

  67. Ojetti V, Pellicano R, Fagoonee S, Migneco A, Berrutti M, Gasbarrini A. Helicobacter pylori infection and diabetes. Minerva Med. 2010;101:115–9.

    CAS  PubMed  Google Scholar 

  68. Aydemir S, Boyacioglu S, Gur G, Demirbilek M, Can FK, Korkmaz M, et al. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. World J Gastroenterol. 2005;11:842–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Jung SW, Lee SW, Hyun JJ, Kim DI, Koo JS, Yim HJ, et al. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease. Dig Liver Dis. 2009;41:134–40.

    Article  CAS  PubMed  Google Scholar 

  70. Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg. 2008;18:1450–4.

    Article  PubMed  Google Scholar 

  71. Brenner H, Rothenbacher D, Bode G, Adler G. Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study. BMJ. 1997;315:1489–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Weisse ME, Eberly B, Person DA. Wine as a digestive aid: comparative antimicrobial effects of bismuth salicylate and red and white wine. BMJ. 1995;311:1657–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Marimon JM, Bujanda L, Gutierrez-Stampa MA, Cosme A, Arenas JI. In vitro bactericidal effect of wine against Helicobacter pylori. Am J Gastroenterol. 1998;93:1392.

    Article  CAS  PubMed  Google Scholar 

  74. Kuepper-Nybelen J, Thefeld W, Rothenbacher D, Brenner H. Patterns of alcohol consumption and Helicobacter pylori infection: results of a population-based study from Germany among 6545 adults. Aliment Pharmacol Ther. 2005;21:57–64.

    Article  CAS  PubMed  Google Scholar 

  75. Nam TM, Lee DH, Kang KP, Lee JH, Chung JI, Choi HC, et al. Clinical factors that potentially affect the treatment outcome of Helicobacter pylori eradication therapy with using a standard triple regimen in peptic ulcer patients. Korean J Gastrointest Endosc. 2008;36:200–5.

    Google Scholar 

  76. Treiber G, Ammon S, Klotz U. Age-dependent eradication of Helicobacter pylori with dual therapy. Aliment Pharmacol Ther. 1997;11:711–8.

    Article  CAS  PubMed  Google Scholar 

  77. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy – results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17:99–109.

    Article  CAS  PubMed  Google Scholar 

  78. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993;88:505–9.

    CAS  PubMed  Google Scholar 

  79. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol. 1994;29:1070–5.

    Article  CAS  PubMed  Google Scholar 

  80. Byun YH, Jo YJ, Kim SC, Lee JS, Shin WY, Park YS, et al. Clinical factors that predicts successful eradication of Helicobacter pylori. Korean J Gastroenterol. 2006;48:172–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Keimyung University School of Medicine, 56 Dalseong-ro, Jung-gu, Daegu, 41931, South Korea

    Ju Yup Lee MD

Authors
  1. Ju Yup Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ju Yup Lee MD .

Editor information

Editors and Affiliations

  1. Seoul National University, Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea (Republic of)

    Nayoung Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Lee, J.Y. (2016). Triple Therapy. In: Kim, N. (eds) Helicobacter pylori. Springer, Singapore. https://doi.org/10.1007/978-981-287-706-2_41

Download citation

  • DOI: https://doi.org/10.1007/978-981-287-706-2_41

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-287-705-5

  • Online ISBN: 978-981-287-706-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation